Stockreport

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

ATAI Life Sciences N.V. - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF - The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study [Read more]